References
- White HD, Chew D. Acute myocardial infarction. Lancet 2008;372:570–84.
- Pfsterer ME, Zellweger MJ, Gersh BJ. Management of stable coronary artery disease. Lancet 2010;375:763–72.
- Frazier L, Johnson RL, Sparks E. Genomics and cardiovascular disease. J Nurs Scholarsh 2005;37(4):315–21.
- Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005;111:3481–8.
- Nordlie MA, Wold LE, Kloner RA. Genetic contributors toward increased risk for ischemic heart disease. J Mol Cell Cardiol 2005;39(4):667–79.
- Winkelmann BR, Hager J. Genetic variation in coronary heart disease and myocardial infarction: methodological overview and clinical evidence. Pharmacogenomics 2000;1(1):73–94.
- Niwa T, Murayama N, Yamazaki H. Oxidation of endobiotics mediated by xenobiotic- metabolizing forms of human cytochrome P450. Curr Drug Metab 2009;10(7):700–12.
- Elbekai RH, El-Kadi AO. Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 2006;112(2):564–87.
- Zordoky BN, El-Kadi AO. Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr Drug Metab 2008;9(2):122–8.
- Taspinar M, Aydos S, Sakiragaoglu O, et al. Impact of genetic variations of the CYP1A1, GSTT1 and GSTM1 genes on the risk of coronary artery disease. DNA Cell Biol 2012;31:211–8.
- Achour A, Zaag I, Gueddah L, et al. Role of CYP1A1 (T6235C) polymorphism and cigarette smoking in the development of coronary heart disease in Tunisian population. J Genet 2011;90:303–7.
- Wang XL, Greco M, Sim AS, et al. Effect of CYP1A1 MspI polymorphism on cigarette smoking related coronary artery disease and diabetes. Atherosclerosis 2002;162:391–7.
- Zhang J, Wang Y, Liu Y, Zhang X. Lack of association between CYP1A1 T6235C polymorphism and coronary artery disease: evidence from a meta-analysis. Mol Med Rep 2013;7(2):543–8.
- Zou JG, Ma YT, Xie X, et al. The association between CYP1A1 genetic polymorphisms and coronary artery disease in the Uygur and Han of China. Lipids Health Dis 2014;13:145.
- US DHHS, Reducing tobacco use: a report of the Surgeon General. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2000, pp. 29–52.
- Franchi E, Marino P, Biondi-Zoccai GG. Transradial versus transfemoral approach for percutaneous coronary procedures. Curr Cardiol Rep 2009;11(5):391–7.
- Lou XY, Chen GB, Yan L, et al. A generalized combinatorial approach for detecting gene-by gene and gene-by-environment interactions with application to nicotine dependence. Am J Hum Genet 2007;80(6):1125–37.
- Manfredi S, Federici C, Picano E, et al. GSTM1, GSTT1 and CYP1A1 detoxification gene polymorphisms and susceptibility to smoking-related coronary artery disease: a case-only study. Mutat Res 2007;621(1–2):106–12.
- Ye H, Li X, Wang L, et al. Genetic associations with coronary heart disease: meta-analyses of 12 candidate genetic variants. Gene 2013;531(1):71–7.
- Hersberger M. Genetic associations with coronary heart disease: meta-analyses of 12 candidate genetic variants. Gene 2015;558(2):299.
- Yeh CC, Sung FC, Kuo LT, et al. Polymorphisms of cytochrome P450 1A1, cigarette smoking and risk of coronary artery disease. Mutat Res 2009;667(1–2):77–81.
- Sultana S, Kolla VK, Peddireddy V, et al. Association of CYP1A1 Gene polymorphism with ischemic stroke in South Indian Population. Transl Stroke Res 2011;2(1):26–32.
- Merhi M, Demirdjian S, Hariri E, et al. Impact of inflammation, gene variants, and cigarette smoking on coronary artery disease risk. Inflamm Res 2015;64(6):415–22.
- Lee AJ, Cai MX, Thomas PE, et al. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 2003;144(8):3382–98.
- Zhu BT. Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab 2002;3(3):321–49.
- Dubey RK, Jackson EK. Cardiovascular protective effects of 17beta-estradiol metabolites. J Appl Physiol (1985) 2001;91(4):1868–83.